In the 4S trial, statin benefit was not significant for individuals without low HDL and high triglycerides.

“Bianca left LDL cholesterol the role of elevated triglycerides and low L HDL in residual CVD risk remaining after statin therapy isn't that an interesting idea and this is exactly what we were talking about earlier that statins really probably do not lower your your cardiovascular risk in secondary prevention trials by lowering LDL and they do it by improving inflammation and the residual risk remains because there is remaining high triglycerides low HDL which is indicative insulin resistance and metabolic syndrome”